期刊文献+

CHK1抑制剂SCH900776抑制胶质瘤细胞U251的增殖及迁移 被引量:2

CHK1 inhibitor SCH900776 suppresses proliferation and migration of U251 cells
下载PDF
导出
摘要 目的:本研究以胶质瘤细胞U251为实验用细胞株,探讨细胞周期检测点激酶1(CHK1)抑制剂SCH900776对其增殖及迁移的影响。方法:MTT法和细胞集落形成实验观察SCH900776对细胞增殖的影响;流式细胞术分析SCH900776对细胞周期分布的影响;划痕实验观察SCH900776对细胞迁移的影响;Western blot实验检测相关蛋白的表达水平。结果:SCH900776能够明显抑制U251细胞的增殖,诱导细胞发生S期或G2/M期阻滞,同时下调细胞分裂周期蛋白2(Cdc2)和p-Cdc2的水平;SCH900776对细胞迁移表现出明显的抑制作用;Western blot结果表明,SCH900776可升高p38丝裂原活化蛋白激酶(MAPK)的磷酸化水平,同时抑制蛋白激酶B(Akt)的磷酸化激活。结论:CHK1抑制剂SCH900776能够抑制胶质瘤细胞U251的增殖与迁移,其机制可能与其激活p38MAPK和抑制Akt活性相关。 AIM: To investigate the effect of SCH900776,an inhibitor of checkpoint kinase 1( CHK1),on the proliferation and migration abilities of human glioma U251 cells. METHODS: The cell viability was detected by MTT assay,and cell proliferation was determined by cell colony formation assay. Cell cycle distribution was analyzed by flow cytometry. Wound healing assay was used to determine the cell migration ability. The protein levels were determined by Western blot. RESULTS: SCH900776 inhibited the growth of U251 cells in a dose-dependent manner( P 〈 0. 05).SCH900776 treatment substantially induced U251 cell cycle arrest in S and G2/M phases by decreasing the level of cell division cycle protein 2( Cdc2) and p-Cdc2. Moreover,SCH900776 inhibited the cell migration. Western blot results indicated that SCH900776 increased the phosphorylation level of p38 MAPK and inhibited the activation of Akt. CONCLUSION: SCH900776 inhibits the proliferation and migration abilities in human U251 cells by promoting the phosphorylation of p38 MAPK and suppressing the activation of Akt.
作者 李召君 李荣耀 王茹 费洪荣 王凤泽 LI Zhao-jun;LI Rong-yao;WANG Ru;FEI Hong-rong;WANG Feng-ze(School of Pharmaceutical Sciences,Taishan Medical University,School of Life Sciences,Taishan Medical Universit)
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2018年第2期200-205,共6页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81272683) 山东省自然科学基金资助项目(No.ZR2016HL58) 山东省高等学校科技计划项目(No.J15LM09)
关键词 细胞周期检测点激酶1 SCH900776 细胞增殖 细胞迁移 胶质瘤 Checkpoint kinase 1 SCH900776 Cell proliferation Cell migration Glioma
  • 相关文献

参考文献3

二级参考文献51

  • 1Lyronis ID, Baritaki S, Bizakis I, et al. K-ras mutation, HPV infection and smoking or alcohol abuse positively cor- relate with esophageal squamous carcinoma [ J ]. Pathol Oncol Res, 2008, 14(3) :267-273.
  • 2Tasioudi KE, Saetta AA, Sakellariou S, et al. pERK acti- vation in esophageal carcinomas: clinicopathological asso- ciations[J]. Pathol Res Pract, 2012, 208(7) : 398-404.
  • 3Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues [ J ]. Future Med Chem, 2011, 3(14) :1787-1808.
  • 4Graziosi L, Mencarelli A, Santorelli C, et al. Mechanistic role of p38 MAPK in gastric cancer dissemination in a ro- dent model peritoneal metastasis [ J ]. Eur J Pharmacol, 2012, 674 ( 2-3 ) : 143-152.
  • 5Sommerer F, Vieth M, Markwarth A, et al. Mutations of BRAF and KRAS2 in the development of Barrett's adeno- carcinoma [ J ]. Oncogene, 2004, 23 (2) : 554- 558.
  • 6Birner P, Jesch B, Schuhheis A, et al. RAF-kinase in- hibitor protein (RKIP) downregulation in esophageal canc- er and its metastases [ J ]. Clin Exp Metastasis, 2012, 29 (6) :551-559.
  • 7Gao C, Pang L, Ren C, et al. Prognostic value of raf ki- nase inhibitor protein in esophageal squamous cell carcino- ma[J]. Pathol Oncol Res, 2012, 18(2) :471- 477.
  • 8Kim HS, Won KY, Kim GY, et al. Reduced expression of Raf-1 kinase inhibitory protein predicts regional lymph node metastasis and shorter survival in esophageal squa- mous cell carcinoma [J]. Pathol Res Pract, 2012, 208 (5) :292- 299.
  • 9Keswani RN, Chumsangsri A, Mustafi R, et al. Sorafenib inhibits MAPK- mediated proliferation in a Barrett's esoph- ageal adenocarcinoma cell line[ J]. Dis Esophagus, 2008, 21(6) :514-521.
  • 10Gao SY, Li EM, Cui L, et al. Spl and AP-1 regulate ex- pression of the human gene VIL2 in esophageal carcinoma cells[ J]. J Biol Chem, 2009, 284(12) :7995- 8004.

共引文献39

同被引文献37

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部